Target Name: MCAM
NCBI ID: G4162
Other Name(s): METCAM | MUC18_HUMAN | melanoma cell adhesion molecule | Cell surface glycoprotein MUC18 | melanoma-associated antigen MUC18 | cell surface glycoprotein P1H12 | HEMCAM | CD146 antigen | melanoma-associated antigen A32 | Gicerin | MUC18 | Melanoma-associated antigen A32 | CD146 | Cell surface glycoprotein P1H12 | MelCAM | melanoma adhesion molecule | Melanoma cell adhesion molecule | S-endo 1 endothelial-associated antigen | Melanoma-associated antigen MUC18

MCAM as A Potential Drug Target for Neurological Disorders

MCAM (METCAM), also known as METCAM-尾, is a protein that is expressed in the brain and has been shown to play a role in the development and progression of several neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. It is a scaffold protein that is involved in the formation of beta-amyloid plaques, which are thought to contribute to the development of these disorders.

Recent studies have suggested that MCAM may be a drug target or biomarker for these disorders. One study published in the journal Nature Medicine used a technique called biochemical assay to identifyMCAM as a potential therapeutic target for Alzheimer's disease. The researchers found thatMCAM levels were significantly reduced in the brains of individuals with Alzheimer's disease compared to those without the disease. They also found that a drug that blockedMCAM increased the number of brain beta-amyloid plaques in the brains of individuals with Alzheimer's disease.

Another study published in the journal Cell used a technique called live-cell imaging to show that MCAM is involved in the formation of beta-amyloid plaques in the brains of individuals with Alzheimer's disease. The researchers found thatMCAM was shown to be directly involved in the formation of beta-amyloid plaques and that this interaction may be a potential therapeutic target for Alzheimer's disease.

MCAM has also been shown to be involved in the progression of Parkinson's disease. A study published in the journal Parkinson's Diseases found thatMCAM levels were significantly reduced in the brains of individuals with Parkinson's disease compared to those without the disease. The researchers also found that a drug that increasedMCAM levels in the brains of individuals with Parkinson's disease improved symptoms of the disease.

Another study published in the journal NeuroImage found that MCAM was involved in the formation of beta-amyloid plaques in the brains of individuals with multiple sclerosis. The researchers found thatMCAM was shown to be involved in the formation of beta-amyloid plaques and that this interaction may be a potential therapeutic target for multiple sclerosis.

In conclusion, studies have shown that MCAM may be a drug target or biomarker for several neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The role ofMCAM in the development and progression of these disorders suggests that it may be a promising target for new treatments. Further research is needed to fully understand the role ofMCAM in these disorders and to develop safe and effective treatments.

Protein Name: Melanoma Cell Adhesion Molecule

Functions: Plays a role in cell adhesion, and in cohesion of the endothelial monolayer at intercellular junctions in vascular tissue. Its expression may allow melanoma cells to interact with cellular elements of the vascular system, thereby enhancing hematogeneous tumor spread. Could be an adhesion molecule active in neural crest cells during embryonic development. Acts as surface receptor that triggers tyrosine phosphorylation of FYN and PTK2/FAK1, and a transient increase in the intracellular calcium concentration

More Common Targets

MCAT | MCC | MCCC1 | MCCC2 | MCCD1 | MCCD1P1 | MCEE | MCEMP1 | MCF2 | MCF2L | MCF2L-AS1 | MCF2L2 | MCFD2 | MCFD2P1 | MCHR1 | MCHR2 | MCHR2-AS1 | MCIDAS | MCL1 | MCM10 | MCM2 | MCM3 | MCM3AP | MCM3AP-AS1 | MCM4 | MCM5 | MCM6 | MCM7 | MCM8 | MCM8-MCM9 complex | MCM9 | MCMBP | MCMDC2 | MCOLN1 | MCOLN2 | MCOLN3 | MCPH1 | MCPH1-AS1 | MCPH1-DT | MCRIP1 | MCRIP2 | MCRS1 | MCTP1 | MCTP2 | MCTS1 | MCTS2 | MCU | MCUB | MCUR1 | MDC1 | MDFI | MDFIC | MDGA1 | MDGA2 | MDH1 | MDH1B | MDH2 | MDK | MDM1 | MDM2 | MDM4 | MDN1 | MDS2 | ME1 | ME2 | ME3 | MEA1 | MEAF6 | MEAF6P1 | MEAK7 | Mechanoelectrical transducer (MET) channel | Mechanosensitive Ion Channel | MECOM | MECOM-AS1 | MeCP1 histone deacetylase (HDAC) complex | MECP2 | MECR | MED1 | MED10 | MED11 | MED12 | MED12L | MED13 | MED13L | MED14 | MED14P1 | MED15 | MED15P8 | MED16 | MED17 | MED18 | MED19 | MED20 | MED21 | MED22 | MED23 | MED24 | MED25 | MED26 | MED27